Show simple item record

dc.contributor.authorWhittam, DH
dc.contributor.authorKarthikeayan, V
dc.contributor.authorGibbons, E
dc.contributor.authorKneen, R
dc.contributor.authorChandratre, S
dc.contributor.authorCiccarelli, O
dc.contributor.authorHacohen, Y
dc.contributor.authorde Seze, J
dc.contributor.authorDeiva, K
dc.contributor.authorHintzen, RQ
dc.contributor.authorWildemann, B
dc.contributor.authorJarius, S
dc.contributor.authorBroadley, S
dc.contributor.authoret al.
dc.date.accessioned2020-07-22T02:55:48Z
dc.date.available2020-07-22T02:55:48Z
dc.date.issued2020
dc.identifier.issn0340-5354
dc.identifier.doi10.1007/s00415-020-10026-y
dc.identifier.urihttp://hdl.handle.net/10072/395681
dc.description.abstractIntroduction: While monophasic and relapsing forms of myelin oligodendrocyte glycoprotein antibody associated disorders (MOGAD) are increasingly diagnosed world-wide, consensus on management is yet to be developed. Objective: To survey the current global clinical practice of clinicians treating MOGAD. Method: Neurologists worldwide with expertise in treating MOGAD participated in an online survey (February–April 2019). Results: Fifty-two responses were received (response rate 60.5%) from 86 invited experts, comprising adult (78.8%, 41/52) and paediatric (21.2%, 11/52) neurologists in 22 countries. All treat acute attacks with high dose corticosteroids. If recovery is incomplete, 71.2% (37/52) proceed next to plasma exchange (PE). 45.5% (5/11) of paediatric neurologists use IV immunoglobulin (IVIg) in preference to PE. Following an acute attack, 55.8% (29/52) of respondents typically continue corticosteroids for ≥ 3 months; though less commonly when treating children. After an index event, 60% (31/51) usually start steroid-sparing maintenance therapy (MT); after ≥ 2 attacks 92.3% (48/52) would start MT. Repeat MOG antibody status is used by 52.9% (27/51) to help decide on MT initiation. Commonly used first line MTs in adults are azathioprine (30.8%, 16/52), mycophenolate mofetil (25.0%, 13/52) and rituximab (17.3%, 9/52). In children, IVIg is the preferred first line MT (54.5%; 6/11). Treatment response is monitored by MRI (53.8%; 28/52), optical coherence tomography (23.1%; 12/52) and MOG antibody titres (36.5%; 19/52). Regardless of monitoring results, 25.0% (13/52) would not stop MT. Conclusion: Current treatment of MOGAD is highly variable, indicating a need for consensus-based treatment guidelines, while awaiting definitive clinical trials.
dc.description.peerreviewedYes
dc.languageEnglish
dc.language.isoeng
dc.publisherSpringer
dc.relation.ispartofjournalJournal of Neurology
dc.subject.fieldofresearchClinical sciences
dc.subject.fieldofresearchNeurosciences
dc.subject.fieldofresearchcode3202
dc.subject.fieldofresearchcode3209
dc.subject.keywordsScience & Technology
dc.subject.keywordsLife Sciences & Biomedicine
dc.subject.keywordsClinical Neurology
dc.subject.keywordsMyelin oligodendrocyte glycoprotein
dc.subject.keywordsNeurology
dc.titleTreatment of MOG antibody associated disorders: results of an international survey
dc.typeJournal article
dc.type.descriptionC1 - Articles
dcterms.bibliographicCitationWhittam, DH; Karthikeayan, V; Gibbons, E; Kneen, R; Chandratre, S; Ciccarelli, O; Hacohen, Y; de Seze, J; Deiva, K; Hintzen, RQ; Wildemann, B; Jarius, S; Broadley, S; et al., A, Treatment of MOG antibody associated disorders: results of an international survey, Journal of Neurology, 2020
dcterms.dateAccepted2020-06-25
dc.date.updated2020-07-22T01:55:05Z
gro.description.notepublicThis publication has been entered in Griffith Research Online as an Advance Online Version.
gro.hasfulltextNo Full Text
gro.griffith.authorBroadley, Simon


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record